ImmuCell (ICCC) Set to Announce Quarterly Earnings on Monday

ImmuCell (NASDAQ:ICCC) will issue its quarterly earnings data after the market closes on Monday, November 13th. Investors that are interested in registering for the company’s conference call can do so using this link.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter. ImmuCell had a negative return on equity of 20.51% and a negative net margin of 38.36%. The company had revenue of $3.53 million for the quarter.

ImmuCell Trading Down 4.8 %

Shares of ImmuCell stock opened at $5.20 on Friday. The company has a quick ratio of 0.81, a current ratio of 2.61 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $5.08 and a 200-day simple moving average of $5.12. ImmuCell has a fifty-two week low of $4.26 and a fifty-two week high of $8.48. The firm has a market cap of $40.30 million, a price-to-earnings ratio of -6.67 and a beta of 0.64.

Institutional Trading of ImmuCell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of ImmuCell by 20.1% in the 2nd quarter. Geode Capital Management LLC now owns 45,727 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 7,645 shares during the period. Cresset Asset Management LLC boosted its stake in ImmuCell by 4.2% in the 1st quarter. Cresset Asset Management LLC now owns 100,506 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 4,080 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ImmuCell by 4.1% during the first quarter. Dimensional Fund Advisors LP now owns 64,689 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 2,519 shares in the last quarter. Morgan Stanley raised its position in ImmuCell by 3.8% during the fourth quarter. Morgan Stanley now owns 76,874 shares of the biotechnology company’s stock valued at $469,000 after buying an additional 2,800 shares during the period. Finally, Vanguard Group Inc. boosted its position in ImmuCell by 22.2% during the 1st quarter. Vanguard Group Inc. now owns 204,325 shares of the biotechnology company’s stock worth $1,972,000 after acquiring an additional 37,081 shares during the period. 13.67% of the stock is owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.